Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.47 |
| ▸ | CASP1 | P29466 | 10/20 | 0.45 |
| ▸ | CASP7 | P55210 | 10/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.45 |
| ▸ | USP2 | O75604 | 8/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.45 |
| ▸ | HBB | P68871 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166859 | 0.80 | ALDH1A1 (0.64) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| SCHEMBL29419105 | 0.80 | ALDH1A1 (0.64) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| SCHEMBL15774206 | 0.79 | ALDH1A1 (0.67) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| SCHEMBL1963785 | 0.77 | ADORA2A (0.55) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| SCHEMBL12553801 | 0.72 | ALDH1A1 (0.51) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL167760 | 0.71 | ALDH1A1 (0.50) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL29419155 | 0.71 | ALDH1A1 (0.50) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| Acetic Acid SCHEMBL5912374 | 0.69 | RPS6KB2 (0.51) | ADORA2AMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL1963097 | 0.69 | ALDH1A1 (0.44) | ADORA2AKLK7MEN1KMT2AKDM4E | |
| SCHEMBL1963094 | 0.69 | HSD17B10 (0.45) | KLK7MEN1KMT2AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143727-B1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8236807-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100015092-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | NAKAJIMA SUANNE | 2010-01-21 | — | — | US | disclosed |
| EP-2143727-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-1615613-B1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7566719-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080152622-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC | 2008-06-26 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1615613-A4 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1615613-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015092-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, HPN | ADORA2A 3710/4885KLK7 1806/4885MEN1 3743/4885 |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, CTSC | ADORA2A 3761/4885KLK7 1832/4885MEN1 3710/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | ADORA2A 3710/4885KLK7 1806/4885MEN1 3743/4885 |
| US-20080152622-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, HPN | ADORA2A 3710/4885KLK7 1806/4885MEN1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.